Top

Gepubliceerd in:

01-09-2007 | Original Paper

Utilities and disutilities for type 2 diabetes treatment-related attributes

Auteurs: Louis S. Matza, Kristina S. Boye, Nicole Yurgin, Jessica Brewster-Jordan, Sally Mannix, Jodi M. Shorr, Beth L. Barber

Gepubliceerd in: Quality of Life Research | Uitgave 7/2007

Abstract

Introduction

Although cost-utility analyses are frequently used to estimate treatment outcomes for type 2 diabetes, utilities are not available for key medication-related attributes. The purpose of this study was to identify the utility or disutility of diabetes medication-related attributes (weight change, gastrointestinal side effects, fear of hypoglycemia) that may influence patient preference.

Methods

Patients with type 2 diabetes in Scotland and England completed standard gamble (SG) interviews to assess utility of hypothetical health states and their own current health state. The EQ-5D, PGWB, and Appraisal of Diabetes Symptoms were administered. Construct validity and differences among health states were examined with correlations, t-tests, and ANOVAs.

Results

A total of 129 patients (51 Scotland; 78 England) completed interviews. Mean utility of diabetes without complications was 0.89. Greater body weight was associated with disutility, and lower body weight with added utility (e.g., 3% higher = −0.04; 3% lower = +0.02). Gastrointestinal side effects and fear of hypoglycemia were associated with significant disutility (p < 0.001). SG utility of current health (mean = 0.87) demonstrated construct validity through correlations with patient-reported outcome measures (r = 0.08–0.31).

Discussion

The vignette-based approach was feasible and useful for assessing added utility or disutility of medication-related attributes.

vorige artikel Reliability and validity of the Pediatric Quality of Life Inventory™ (PedsQL™) Short Form 15 Generic Core Scales in Japan

volgende artikel Emergency physicians’ pain judgments: cluster analyses on scenarios of acute abdominal pain

Feeny, D., Barr, R. D., Furlong, W., et al. (1991). Quality of life of the treatment process in pediatric oncology: An approach to measurement. In D. Osaba (Ed.), Effect of cancer on quality of life. Boca Raton, FL: CRC Press.

Torrance, G. W., Furlong, W., & Feeny, D. (2002). Health utility estimation. Expert Review of Pharmacoeconomics Research, 2(2), 99–108.CrossRef

Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5(1), 1–30.PubMedCrossRef

Torrance, G. W. (1996). Designing and conducting cost-utility analyses. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed.). Philadelphia, PA: Lippincott-Raven Publishers.

Clarke, P. M., Gray, A. M., Briggs, A., et al. (2005). Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 48(5), 868–877.PubMedCrossRef

Eddy, D. M., Schlessinger, L., & Kahn, R. (2005). Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Annals of Internal Medicine, 143(4), 251–264.PubMed

McEwan, P., Peters, J. R., Bergenheim, K., et al. (2006). Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research and Opinion, 22(1), 121–129.PubMedCrossRef

Palmer, A. J., Roze, S., Valentine, W. J., et al. (2004). The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion, 20(Suppl 1), S5–S26.PubMedCrossRef

Warren, E., Weatherley-Jones, E., Chilcott, J., et al. (2004). Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment, 8(45), iii, 1–57.

10.

Zhou, H., Isaman, D. J., Messinger, S., et al. (2005). A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care, 28(12), 2856–2863.PubMedCrossRef

11.

DeFronzo, R. A., Ratner, R. E., Han, J., et al. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28(5), 1092–1100.PubMedCrossRef

12.

Heller, S. (2004). Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 65(Suppl 1), S23–S27.PubMedCrossRef

13.

Purnell, J. Q., & Weyer, C. (2003). Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity. Treatments in Endocrinology, 2(1), 33–47.PubMedCrossRef

14.

Albu, J., & Raja-Khan, N. (2003). The management of the obese diabetic patient. Primary Care, 30(2), 465–491.PubMed

15.

The Diabetes Control, Complications Trial (DCCT) Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329(14), 977–986.CrossRef

16.

Scheen, A. J. (2000). Treatment of diabetes in patients with severe obesity. Biomedicine & Pharmacotherapy, 54(2), 74–79.CrossRef

17.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). (1998). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352(9131), 837–853.

18.

Blonde, L., Dailey, G. E., Jabbour, S. A., et al. (2004). Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: Results of a retrospective cohort study. Current Medical Research and Opinion, 20(4), 565–572.PubMedCrossRef

19.

Heine, R. J., Van Gaal, L. F., Johns, D., et al. (2005). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Annals of Internal Medicine, 143(8), 559–569.PubMed

20.

Marshall, V., Wilton, L., & Shakir S. (2006). Safety profile of repaglinide as used in general practice in England: Results of a prescription-event monitoring study. Acta Diabetologica, 43(1), 6–13.PubMedCrossRef

21.

Warren, E., Weatherley-Jones, E., Chilcott, J., et al. (2006) Assessment report: The clinical and cost-effectiveness of long-acting insulin analogue, insulin glargine. [Online]. Available at: http://www.nice.org.uk/pdf/Insulin_Analogues.pdf. Accessed 2006, January 26.

22.

de Galan, B. E., Schouwenberg, B. J., Tack, C. J., et al. (2006). Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes. The Netherlands Journal of Medicine, 64(8), 269–279.PubMed

23.

McQueen, J. (2005). Pramlintide acetate. American Journal of Health-System Pharmacy, 62(22), 2363–2372.PubMedCrossRef

24.

Costea, M., Ionescu-Tirgoviste, C., Cheta, D., et al. (1993). Fear of hypoglycemia in type 1 (insulin-dependent) diabetic patients. Romanian Journal of Internal Medicine, 31(4), 291–295.PubMed

25.

de Grauw, W. J., van de Lisdonk, E. H., van Gerwen, W. H., et al. (2001). Insulin therapy in poorly controlled type 2 diabetic patients: Does it affect quality of life? The British Journal of General Practice, 51(468), 527–532.PubMed

26.

Irvine, A. A., Cox, D., & Gonder-Frederick, L. (2002). Fear of hypoglycemia: Relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychology, 11, 135–138.CrossRef

27.

Marrero, D. G., Guare, J. C., Vandagriff, J. L., et al. (1997). Fear of hypoglycemia in the parents of children and adolescents with diabetes: Maladaptive or healthy response? The Diabetes Educator, 23(3), 281–286.PubMedCrossRef

28.

Weinberger, M., Kirkman, M. S., Samsa, G. P., et al. (1994). The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Medical Care, 32(12), 1173–1181.PubMedCrossRef

29.

Bagust, A., & Beale S. (2005). Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics, 14(3), 217–230.PubMedCrossRef

30.

Clarke, P., Gray, A., & Holman, R. (2002). Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making, 22(4), 340–349.PubMedCrossRef

31.

Koopmanschap, M. (2002). Coping with Type II diabetes: The patient’s perspective. Diabetologia, 45(7), S18–S22.PubMed

32.

Lee, A. J., Morgan, C. L., Morrissey, M., et al. (2005). Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabetic Medicine, 22(11), 1482–1486.PubMedCrossRef

33.

Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., et al. (2002). Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25(3), 458–463.PubMedCrossRef

34.

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). (1999). UK Prospective Diabetes Study Group. Diabetes Care, 22(7), 1125–1136.

35.

Coffey, J. T., Brandle, M., Zhou, H., et al. (2002). Valuing health-related quality of life in diabetes. Diabetes Care, 25(12), 2238–2243.PubMedCrossRef

36.

Maddigan, S. L., Feeny, D. H., & Johnson, J. A. (2003). A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes. Medical Decision Making, 23(6), 489–501.PubMedCrossRef

37.

Maddigan, S. L., Majumdar, S. R., Toth, E. L., et al. (2003). Health-related quality of life deficits associated with varying degrees of disease severity in type 2 diabetes. Health and Quality of Life Outcomes, 1(1), 78.PubMedCrossRef

38.

Brazier, J., Roberts, J., Tsuchiya, A., et al. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884.PubMedCrossRef

39.

Brazier, J., Jones, N., & Kind, P. (1993). Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Quality of Life Research, 2(3), 169–180.PubMedCrossRef

40.

Hinz, A., Klaiberg, A., Brahler, E., et al. (2006). The Quality of Life Questionnaire EQ-5D: modelling and norm values for the general population. Psychotherapie, Psychosomatik, Medizinische Psychologie, 56(2), 42–48.PubMedCrossRef

41.

Kaarlola, A., Pettila, V., & Kekki, P. (2004). Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients. Intensive Care Medicine, 30(12), 2245–2252.PubMedCrossRef

42.

Stein, K., Fry, A., Round, A., et al. (2005). What value health?: A review of health state values used in early technology assessments for NICE. Applied Health Economics and Health Policy, 4(4), 219–228.PubMedCrossRef

43.

Gafni, A. (1994). The standard gamble method: What is being measured and how it is interpreted. Health Services Research, 29(2), 207–224.PubMed

44.

Torrance, G. W., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care, 5(4), 559–575.PubMedCrossRef

45.

Revicki, D. A., & Wood, M. (1998). Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications. Journal of Affective Disorders, 48(1), 25–36.PubMedCrossRef

46.

Matza, L. S., Secnik, K., Rentz, A. M., et al. (2005). Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Quality of Life Research, 14, 735–747.PubMed

47.

Secnik, K., Matza, L. S., Cottrell, S., et al. (2005). Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Medical Decision Making, 25(1), 56–70.PubMedCrossRef

48.

Bass, E. B., Steinberg, E. P., Pitt, H. A., et al. (1994). Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Medical Decision Making, 14(4), 307–314.PubMedCrossRef

49.

Cook, J., Richardson, J., & Street, A. (1994). A cost utility analysis of treatment options for gallstone disease: Methodological issues and results. Health Economics, 3(3), 157–168.PubMedCrossRef

50.

Feeny, D. H., & Torrance, G. W. (1989). Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Medical Care, 27(3 Suppl), S190–S204.PubMedCrossRef

51.

Johnston, K., Brown, J., Gerard, K., et al. (1998). Valuing temporary and chronic health states associated with breast screening. Social Science & Medicine, 47(2), 213–222.CrossRef

52.

Stalmeier, P. F. (2002). Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Medical Decision Making, 22(1), 53–64.PubMedCrossRef

53.

Mauskopf, J. (2006). Utility assessment. In E. C. G. Chumney, & K. N. Simpson (Eds.), Methods and designs for outcomes research. Bethesda, MD: American Society of Health-System Pharmacists.

54.

Rutten-van Molken, M. P., Bakker, C. H., van Doorslaer, E. K., et al. (1995). Methodological issues of patient utility measurement. Experience from two clinical trials. Medical Care, 33(9), 922–937.PubMedCrossRef

55.

Carey, M. P., Jorgensen, R. S., Weinstock, R. S., et al. (1991). Reliability and validity of the appraisal of diabetes scale. Journal of Behavioral Medicine, 14(1), 43–51.PubMedCrossRef

56.

Brooks, R., Rabin, R., & de Charro, F. (Eds.) (2003). The measurement and valuation of health status using EQ-5D: A European perspective. Dordrecht: Kluwer Academic Publishers.

57.

EuroQol Group. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef

58.

Krabbe, P., & Weijnen, T. (2003). Guidelines for analysing and reporting EQ-5D outcomes. In R. Brooks, R. Rabin, & F. de Charro (Eds.), The measurement and valuation of health status using EQ-5D: A European perspective. Dordrecht: Kluwer Academic Publishers.

59.

McDowell, I., & Newell C. (1996). Measuring health: A guide to rating scales and questionnaires (2nd ed.). New York: Oxford University Press.

60.

Jia, H., & Lubetkin, E. I. (2005). The impact of obesity on health-related quality-of-life in the general adult US population. Journal of Public Health (Oxford, England), 27(2), 156–164.CrossRef

61.

Dupuy, H. J. (1984). The Psychological General Well-Being (PGWB) index. In N. K. Wenger, M. E. Mattson, C. D. Furberg, et al. (Eds.), Assessment of quality of life in clinical trials of cardiovascular therapies (pp 170–183). Washington, DC: Le Jacq Publishing.

62.

Chassany, O., Dimenas, E., Dubois, D., et al. (2004). PGWBI user manual. Lyon, France: MAPI Research Institute.

63.

Leonardson, G. R., Daniels, M. C., Ness, F. K., et al. (2003). Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychological Reports, 93(1), 49–58.PubMedCrossRef

64.

Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.

65.

Garrow, J. S., & Webster, J. (1985). Quetelet’s index (W/H2) as a measure of fatness. International Journal of Obesity, 9(2), 147–153.PubMed

66.

Foxcroft, D. R., & Milne, R. (2000). Orlistat for the treatment of obesity: Rapid review and cost-effectiveness model. Obesity Reviews, 1(2), 121–126.PubMedCrossRef

67.

Groessl, E. J., Kaplan, R. M., Barrett-Connor, E., et al. (2004). Body mass index and quality of well-being in a community of older adults. American Journal of Preventive Medicine, 26(2), 126–129.PubMedCrossRef

68.

Hakim, Z., Wolf, A., & Garrison, L. P. (2002). Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics, 20(6), 393–404.PubMedCrossRef

69.

Brohan, E. M., Wild, D. J., Wittrup-Jensen, K. U., et al. (2005). Fear of hypoglycemia: A review of the literature. Poster presented at the Annual Meeting of the International Society for Quality of Life Research (ISOQOL); October 19–22, San Francisco, CA.

70.

Blumenschein, K., & Johannesson, M. (1998). Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Annals of Allergy, Asthma & Immunology, 80(2), 189–194.CrossRef

71.

Green, C., Kiebert, G., Murphy, C., et al. (2003). Patients’ health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis. Quality of Life Research, 12(5), 565–574.PubMedCrossRef

72.

Juniper, E. F., Norman, G. R., Cox, F. M., et al. (2001). Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma. The European Respiratory Journal, 18(1), 38–44.PubMedCrossRef

73.

Kartman, B., Gatz, G., & Johannesson, M. (2004). Health state utilities in gastroesophageal reflux disease patients with heartburn: A study in Germany and Sweden. Medical Decision Making, 24(1), 40–52.PubMedCrossRef

74.

Ohsawa, I., Ishida, T., Oshida, Y., et al. (2003). Subjective health values of individuals with diabetes in Japan: Comparison of utility values with the SF-36 scores. Diabetes Research and Clinical Practice, 62(1), 9–16.PubMedCrossRef

75.

Stavem, K. (1998). Quality of life in epilepsy: Comparison of four preference measures. Epilepsy Research, 29(3), 201–209.PubMedCrossRef

76.

Sullivan, S. D., Lew, D. P., & Devine, E. B., et al. (2002). Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics, 20(15), 1079–1089.PubMedCrossRef

77.

Jansen, S. J., Stiggelbout, A. M., Wakker, P. P., et al. (1998). Patients’ utilities for cancer treatments: A study of the chained procedure for the standard gamble and time tradeoff. Medical Decision Making, 18(4), 391–399.PubMedCrossRef

78.

Bleichrodt, H., Pinto, J. L., & Abellan-Perpinan, J. M. (2003). A consistency test of the time trade-off. Journal of Health Economics, 22(6), 1037–1052.PubMedCrossRef

79.

Torrance, G. W. (1997). Preferences for health outcomes and cost-utility analysis. The American Journal of Managed Care, 3(Suppl), S8–S20.PubMed

80.

National Institute for Clinical Excellence (NICE). (2003). Guide to the methods of technology appraisal. London: NICE.

81.

Drummond, M. F., O’Brien, B., Stoddart, G. L., et al. (2000). Methods for the economic evaluation of health care programmes (2nd ed.). Oxford University Press.

Titel: Utilities and disutilities for type 2 diabetes treatment-related attributes
Auteurs: Louis S. Matza
Kristina S. Boye
Nicole Yurgin
Jessica Brewster-Jordan
Sally Mannix
Jodi M. Shorr
Beth L. Barber
Publicatiedatum: 01-09-2007
Uitgeverij: Springer Netherlands
Gepubliceerd in: Quality of Life Research / Uitgave 7/2007
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-007-9226-0

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Introduction

Methods

Results

Discussion

Log in om toegang te krijgen

Andere artikelen Uitgave 7/2007

Reliability and validity of the Pediatric Quality of Life Inventory™ (PedsQL™) Short Form 15 Generic Core Scales in Japan

Change in health status and mortality as indicators of outcomes: comparison between the Medicare Advantage Program and the Veterans Health Administration

Validity of patient-reported health-related quality of life global ratings of change using structural equation modeling

How can quality of life researchers make their work more useful to health workers and their patients?

Factors associated with participation restriction in community-dwelling adults aged 50 years and over

Emergency physicians’ pain judgments: cluster analyses on scenarios of acute abdominal pain